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ABSTRACT 
 
Gliomatosis cerebri (GC) is presently considered a distinct astrocytic glioma entity according 
to the WHO classification for CNS tumors. It is characterized by widespread, typically 
bilateral infiltration of the brain involving three or more lobes. Genetic studies of GC have to 
date been restricted to the analysis of individual glioma-associated genes, which revealed 
mutations in the isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 (TP53) genes in 
subsets of patients. Here, we report on a genome-wide analysis of DNA methylation and 
copy number aberrations in 25 GC patients. Results were compared with those obtained for 
105 patients with various types of conventional, i.e., non-GC gliomas including diffuse 
astrocytic gliomas, oligodendrogliomas and glioblastomas. In addition, we assessed the 
prognostic role of methylation profiles and recurrent DNA copy number aberrations in GC 
patients. Our data reveal that the methylation profiles in 23 of the 25 GC tumors 
corresponded to either IDH mutant astrocytoma (n=6), IDH mutant and 1p/19q codeleted 
oligodendroglioma (n=5), or IDH wildtype glioblastoma including various molecular 
subgroups, i.e., H3F3A-G34 mutant (n=1), receptor tyrosine kinase 1 (RTK1, n=4), receptor 
tyrosine kinase 2 (classic) (RTK2, n=2) or mesenchymal (n=5) glioblastoma groups. Two 
tumors showed methylation profiles of normal brain tissue due to low tumor cell content. 
While histological grading (WHO grade IV vs. WHO grade II and III) was not prognostic, the 
molecular classification as classic/RTK2 or mesenchymal glioblastoma was associated with 
worse overall survival. Multivariate Cox regression analysis revealed MGMT promoter 
methylation as a positive prognostic factor. Taken together, DNA-based large-scale 
molecular profiling indicates that GC comprises a genetically and epigenetically 
heterogeneous group of diffuse gliomas that carry DNA methylation and copy number 
profiles closely matching the common molecularly defined glioma entities. These data 
support the removal of GC as a distinct glioma entity in the upcoming revision of the WHO 
classification. 
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INTRODUCTION 
 
Gliomatosis cerebri (GC) is a rare glial neoplasm characterized by extensive infiltration of the 
brain involving three or more cerebral lobes [6]. Bilateral tumor growth is frequent, and GC 
may also extend to infratentorial structures and even the spinal cord. Histologically, GC 
corresponds to diffusely infiltrating, mostly astrocytic gliomas of World Health Organization 
(WHO) grades II, III or IV [6]. GC with histological features of oligodendroglial differentiation 
have also been reported but are less frequent [21]. Although the current WHO classification 
of brain tumors [6] lists GC as a separate glial entity, this entity is not well defined beyond the 
criteria mentioned above. The highly variable course of disease, with median survival of 
about 30 months after diagnosis and broad variation from a few months to >40 months 
[7,8,21], also challenges the view that GC comprises a distinct glioma entity. Moreover, 
molecular studies on GC have reported genetic alterations that are also common in diffuse 
and anaplastic astrocytic gliomas or glioblastomas, such as isocitrate dehydrogenese 1 
(IDH1) mutation, tumor protein 53 (TP53) mutation and epidermal growth factor receptor 
(EGFR) amplification [4,5,7,9,11,13,14,18,21]. No GC-specific genetic alteration or molecular 
signature has been reported to date. Overall, data on genetic and epigenetic aberrations in 
GC are scarce, and systematic analyses on larger cohorts of patients with well-documented 
clinical annotation are missing. The purpose of the present study was therefore to apply 
genome-wide DNA methylation and DNA copy number profiling to a multicenter cohort of 
clinically well-annotated GC cases, and to compare the respective aberration profiles with 
those typically present in the more common and molecularly well-defined types of diffuse 
gliomas, i.e., diffuse astrocytic and oligodendroglial gliomas as well as glioblastomas. We 
thereby aimed to answer the question, whether GC is indeed a distinct glial tumor entity that 
is characterized by specific genetic and/or epigenetic aberrations. 
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PATIENTS AND METHODS 
 
Patients and neuroimaging  
The clinical databases of the Division of Clinical Neurooncology, University of Bonn, the 
Department of Neurology, University of Zurich, and the repository of the NOA-05 trial [7] 
were retrospectively screened for patients fulfilling the following criteria: (1) adult (>18 years 
old) patient, (2) histologically proven diffuse glioma corresponding to astrocytoma, 
oligoastrocytoma or oligodendroglioma WHO grade II or III, or glioblastoma WHO grade IV 
confirmed by central pathology review (G.R.), and (3) tumor extent meeting the WHO criteria 
of GC, i.e., widespread infiltration of three or more cerebral lobes on T2-weighted MRI 
confirmed by central radiological review (E.H., U.H.). To determine the number of central 
nervous system (CNS) regions involved, the frontal, temporal, parietal, and occipital lobes of 
both sides were regarded as separate regions. Also, the basal ganglia including thalamus of 
both sides each, brain stem and cerebellum, and spinal cord were regarded as separate 
regions. (4) For all patients to be included, paraffin-embedded tumor tissue had to be 
available for extraction of sufficient amounts of DNA for methylation profiling. All local Ethics 
Committees approved clinical data collection and molecular analyses. All MRIs were 
evaluated for the extent of T2 hyperintensities (number of lobes involved), involvement of 
both hemispheres and focal contrast-enhancement. As previously described [7], all patients 
were evaluated for the presence of bilateral symmetric GC, i.e., the involvement of the same 
number of lobes of both sides.  
 
Histological classification and extraction of tumor DNA 
All tumor samples were histologically classified according to the criteria of the WHO 
classification of tumors of the central nervous system [6|. Histology revealed an estimated 
tumor cell content of at least 60% in the investigated tissue specimens except for two cases 
with estimated tumor cell contents of approximately 20%. Tumor DNA was extracted from 
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formalin-fixed paraffin-embedded tissue sections using the QIAamp DNA FFPE Tissue Kit 
(Qiagen, Hilden, Germany).  
 
Array-based DNA methylation and copy number profiling 
To evaluate molecular subgroups of GC, we performed comparative cluster analysis of DNA 
methylation profiles generated for 25 GC tissue samples using the Illumina Infinium® 
HumanMethylation450 beadchip technology (‘450k array’). DNA methylation profiles 
obtained for the 25 gliomatosis cerebri cases were evaluated together with DNA methylation 
profiles of 105 other gliomas, including 45 isocitrate dehydrogenase (IDH) and H3 histone, 
family 3A (H3F3A) wildtype glioblastomas, 15 H3F3A-G34 mutant glioblastomas, 15 H3F3A-
K27 mutant glioblastomas, 15 IDH mutant astrocytic gliomas, and 15 IDH mutant 1p/19q 
codeleted oligodendroglial tumors. DNA methylation profiles obtained from ten normal 
cerebral hemisphere tissue samples were also included in the analyses. Individual samples 
were normalized by performing background correction and dye bias correction (shifting of 
negative control probe mean intensity to zero and scaling of normalization control probe 
mean intensity to 10,000, respectively). As reported before [10,19], the following probe 
filtering criteria were applied: removal of probes targeting the X and Y chromosomes (n = 
11,551), removal of probes containing a single-nucleotide polymorphism (dbSNP132 
Common) within five base pairs of and including the targeted CpG-site (n = 24,536), and 
probes not mapping uniquely to the human reference genome (hg19) allowing for one 
mismatch (n = 9,993). In total, 438,370 probes were kept for analysis. 
 
For unsupervised hierarchical clustering of the 140 samples, we selected the 13,248 most 
variably methylated probes across the dataset (using a cut-off of standard deviation >0.25). 
Samples were clustered using 1-Pearson correlation coefficient as the distance measure and 
average linkage (x-axis). Methylation probes were reordered by hierarchical clustering using 
Euclidean distance and average linkage (y-axis). Unscaled methylation levels were depicted 
7	
	
in a heatmap ranging from unmethylated state (beta-value: 0.0, blue color) to 
hemimethylated (0.5, white) and fully methylated state (1.0, red). 
 
In addition to DNA methylation profiling, we performed copy-number variation (CNV) analysis 
with data from the 450k arrays using the ‘conumee’ package for the R statistical environment 
(available at: http://www.bioconductor.org/packages/release/bioc/html/conumee.html). For 
the detection of amplifications and chromosomal gains and losses, automatic scoring was 
verified by manual assessment of the respective loci for each individual profile [10,19]. The 
MGMT promoter methylation status and the presence of the glioma CpG island methylator 
phenotype (CIMP) were determined based on 450k array data [1,24].  
 
 
Survival and prognostic factors  
Overall survival was calculated according to Kaplan and Meier from the day of diagnosis of 
GC, i.e., the day when both histological and imaging criteria were fulfilled for the first time, 
until death. Differences between subgroups were compared using the logrank test. 
Prognostic factors derived from molecular subgroups or dichotomized imaging parameters 
were analyzed by univariate Cox regression analysis. Multivariate analysis was performed 
with parameters showing differences between the subgroups with a significance of 0.1 or 
less. The correlation between dichotomized imaging and molecular parameters on 2 x 2 
tables was determined using the chi square test.  
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RESULTS 
 
Patient characteristics 
Queries of the databanks of the Division of Clinical Neurooncology, University of Bonn (n=8), 
the Department of Neurology, University of Zurich (n=6) and the NOA-05 trial repository 
(n=11) revealed 25 patients with an unequivocal diagnosis of GC. This required the 
involvement of three or more brain lobes as determined by reference neuroradiology, in 
conjunction with biopsy specimens showing a diffusely infiltrating glioma with sufficient tumor 
material for genome-wide methylome analysis. The 11 patients of the NOA-05 trial were 
included in a previous publication reporting on clinical outcomes, MRI characteristics and 
selected genetic alterations such as IDH1 mutation and MGMT promoter methylation [7].  
 
Individual patient data are provided in Table 1. Table 2 summarizes the patients’ clinical and 
imaging characteristics. Median age at diagnosis was 50.3 years (range 23.6-76.9 years). 
One third of the patients demonstrated a glioblastoma histology upon biopsy, while 
oligodendroglial differentiation was less common (20%) (Table 2). Half of the tumors were 
particularly extensive tumors and involved six or more lobes; most of the patients (88%) had 
bilateral involvement at the time of first diagnosis. Focal contrast enhancement at diagnosis 
of GC (i.e. ‘Type 2’ GC) was seen in 14 of 25 patients (56%). Figure 1 shows 
neuroradiological features in selected cases representing different histological and molecular 
glioma entities. Of the 25 patients, 2 received no chemo- or radiotherapy, 3 had radiotherapy 
alone as primary therapy, 14 had alkylating chemotherapy (13 procarbacin/CCNU, 1 
temozolomide) and 6 patients received combined radiotherapy with concomitant and 
adjuvant temozolomide.  
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450k methylation profiling 
Large-scale DNA methylation profiling analysis using 450k beadchip arrays revealed distinct 
methylation profiles in GC (Figure 2). Twenty-three of 25 samples could be assigned to one 
of the previously described epigenetic subgroups [19,23] of diffuse gliomas including IDH 
mutant astrocytoma (A_IDH: n=6; 24%), IDH mutant and 1p/19q codeleted 
oligodendroglioma (O_IDH: n=5; 20%), IDH wildtype glioblastoma (GBM) receptor tyrosine 
kinase (RTK) subgroup 1 (GBM_RTK1: n=4; 16%), IDH wildtype glioblastoma RTK2 (classic) 
subgroup (GBM_RTK2: n=2; 8%), IDH wildtype glioblastoma mesenchymal subgroup 
(GBM_mes: n=5; 20%), and glioblastoma H3F3A-G34 mutant in the 24-year-old, youngest 
patient of the cohort (GBM_G34; n=1; 4%). In 2 of 25 tumors, i.e. the two tumors with low 
tumor cell content, the normal brain tissue background was too high for adequate 
assignment to a specific glioma-associated methylation group, i.e., the methylation profiles in 
these cases corresponded most closely to a normal brain profile. DNA methylation profiling 
analysis did not reveal a previously unreported new subgroup of glioma enriched in this GC 
cohort. 
 
In 23 of 25 tumor samples both a histological classification and a distinct glioma-associated 
methylation profile were available (Table 1). With conventional histology, 10/23 tumors were 
classified as glioblastoma WHO grade IV while 13/23 tumors were classified as diffuse or 
anaplastic gliomas corresponding to WHO grade II or III, 5 of them with a significant 
oligodendroglial component. With the use of DNA methylation profiling, the number of GC 
demonstrating an IDH wildtype glioblastoma-associated methylation profile increased to 12 
tumors. Three GC tumors diagnosed histologically as WHO grade II or III gliomas showed 
methylation and copy number profiles typical for IDH wildtype glioblastoma WHO grade IV. 
One GC tumor histologically classified as glioblastoma demonstrated a DNA methylation 
profile corresponding to IDH mutant astrocytic gliomas. A concordance between histological 
diagnosis and DNA methylation-based classification was found in 19 of 23 cases.  
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Survival and prognostic value of histology and molecular subgroups 
The median overall survival (mOS) of the whole patient cohort was 34.6 months (95% CI 7.1-
62.1 months). The course of disease was highly variable, with 26.2% of patients having an 
overall survival time of less than 12 months and 49.2% of patients surviving for more than 3 
years. Histological grading (WHO grade IV vs. WHO grades II/III) was not prognostic. Median 
OS was 34.6 months (95% CI not assessable) in the WHO grade II/III group and 36.2 
months (95% CI 7.6-64.9 months) in the WHO grade IV group (p= 0.62, logrank test; Fig. 
3a). The separation of cases according to IDH mutation / CpG island methylator phenotype 
(CIMP) status yielded borderline significance (p=0.08) for survival curves with median OS of 
36.2 months for patients with IDH mutant / CIMP positive tumors (95% CI 32.9-39.6 months) 
as opposed to 14.1 months for patients with IDH wildtype/CIMP negative tumors (95% CI 
11.1-17.1 months). When the GC patients belonging to the GBM_mes or GBM_RTK2 
subgroups were compared to all other patients, differences between the groups regarding 
overall survival were highly significant: Median OS was 37.1 months (95%CI 35-39.2) in the 
group of patients with GC tumors molecularly corresponding to Astro_IDH, Oligo_IDH, 
GBM_RTK1 or GBM_G34 subgroups but only 12.2 months (5.9-18.4 months) in the group of 
patients with GBM_mes or GBM_RTK2 subgroup tumors (p=0.002; Fig. 3b). Also, univariate 
Cox analyses (Table 3) confirmed a significant negative effect when GBM_mes or 
GBM_RTK2 glioblastomas were compared with all other tumors, while no significant effect 
was found for histological grading (WHO grade IV vs. WHO grade II and III) or the separation 
of all molecularly defined glioblastomas from any other tumors (Table 3). A comparison of 
overall survival between the 6 patients with Astro_IDH and the 5 patients with Oligo_IDH 
group tumors revealed no significant difference (p=0.32). This finding is likely due to the 
small numbers of patients in each group and the relatively short follow-up for 4 of 5 patients 
in the Oligo_IDH group.  
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MGMT promoter methylation and selected DNA copy number aberrations 
The results of the MGMT promoter methylation analysis and DNA copy number variations 
(CNV) analysis for selected genes/chromosomal regions are summarized in Table 1. MGMT 
promoter hypermethylation was found in 14 of 22 evaluable tumors. The following further 
genetic alterations were frequently found in this GC cohort (Table 1): 1p/19q codeletion (5/24 
tumors), chromosome 7 gain (9/24 tumors), focal deletion at 9p21 (CDKN2A/B) (7/24 
tumors), and chromosome 10 loss (8/24 tumors). Univariate Cox regression analysis 
revealed that MGMT promoter methylation was a positive prognostic factor (Table 4), while 
chromosome 7 gain and EGFR amplification (detected in 3/24 tumors) were negative 
prognostic factors. In a multivariate Cox analysis (Table 4) only MGMT promoter methylation 
remained a significant prognostic factor with superior overall survival for patients with a tumor 
harbouring a methylated MGMT promotor (Fig. 3c). Codeletion of 1p/19q was not prognostic, 
likely due to the fact that 4 of the 5 patients were censored at rather short follow-up times 
between 14-17 months.  
 
 
Imaging features: prognostic value and association with molecular findings 
Bihemispheric involvement, involvement of infratentorial structures, presence of a contrast-
enhancing lesion on the first MRI fulfilling GC criteria or high lesion load with involvement of 
six or more regions of the brain were not associated with worse prognosis on univariate Cox 
regression analysis (Table 5).  
 
The presence of a methylated MGMT promoter, IDH mutation / CIMP positivity, chromosome 
7 gain or EGFR amplification did not correlate with the key imaging features, i.e., initial 
contrast enhancement, involvement of 6 regions or diffuse-symmetric involvement (p>0.05 
for all analyses, chi square test). The histological detection of a WHO grade IV tumor was 
significantly associated with the presence of a contrast-enhancing lesion (p= 0.02, Chi  
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square test) and a high lesion load with involvement of 6 or more regions (p=0.02). However, 
the prognostically relevant detection of a molecularly defined GBM_MES or GBM_RTK2 
tumor was not significantly associated with contrast-enhancing lesions (p=0.28) or high 
lesion load with involvement of 6 regions (p=0.30).  
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DISCUSSION 
 
In the present cohort of 25 patients with GC, genome-wide DNA methylation and copy 
number profiling data provided evidence that GC tissue specimens with sufficient tumor cell 
content can unequivocally be assigned to known molecularly defined subgroups of non-GC 
diffuse gliomas. There was no evidence for a distinct GC-specific molecular subgroup. 
MGMT promoter methylation was the only significant single gene prognostic factor in this GC 
cohort that included a high percentage of GBM patients (40% GBMs defined histologically, 
50% GBMs defined molecularly) and patients with alkylating chemotherapy (80%) as part of 
their first-line therapy.  
 
Large-scale DNA methylation profiling using Infinium® HumanMethylation450 beadchip 
arrays has proven very useful for the elucidation of biologically distinct subgroups of 
medulloblastoma [10], ependymoma [15], glioblastoma [2,12,19], as well as diffuse and 
anaplastic gliomas [16,17,23]. In the present study of GC patients, 450k analyses revealed 
that DNA methylation profiles corresponded to those of several previously defined molecular 
subgroups of gliomas. Most importantly, this analysis did not demonstrate evidence for a 
distinct GC signature. This finding is in line with previous publications reporting on single 
gene alterations [4,5,7,11,13,14] or CGH patterns [22] typical for other glioma entities in 
smaller series of GC samples. Admittedly, the number of cases analyzed in the present 
cohort was also relatively small due to the general rarity of GC and the fact that for this 
retrospective analysis a sufficient amount of tumor tissue was necessary. It cannot be 
excluded that the requirement for a suitable amount of tissue may have introduced some 
bias to the selection of patients for molecular profiling. Nevertheless, the lack of a single 
specimen in our series (beyond the two samples hampered by too high normal cell count) 
that could not be assigned to one of the known glioma subgroups raises doubt that in much 
larger cohorts of GC patients a substantial number of tumors could be identified that would 
form a distinct and not yet described molecular GC subgroup.  
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Epigenome-wide methylation profiling appears to be highly valuable for classification and 
prognostic purposes. In this GC cohort, 10 of 25 tumors were classified as glioblastoma 
WHO grade IV by histological analysis while DNA methylation profiling revealed IDH wildtype 
glioblastoma-associated DNA methylation signatures in 12/23 evaluable tumors. Thus, 
similar to data recently reported for diffuse and anaplastic astrocytic gliomas [3,16,20,23], 
450k beadchip-based DNA methylation profiling may lead to a refined diagnosis of GC 
tumors. This appears to be both biologically and clinically meaningful, since methylation 
profiling but not focal histology allowed for the identification of a subgroup of GC with poor 
prognosis. This group consists of patients with IDH wildtype glioblastomas corresponding to 
the GBM_RTK2 and GBM_MES subtypes (Table 3, Figs. 2 and 3B). These two subtypes 
constitute the two most common glioblastoma groups in adult patients [19]. In contrast, 
classification and grading of the GC cases according to histological criteria alone was not 
prognostically relevant. As a cautionary remark, it has to be kept in mind that these results 
have been obtained in a relatively small cohort of patients: Small changes in the composition 
of the subgroups were sufficient to alter the statistical significance of the analysis. 
 
MRI analysis in our cohort did not reveal any imaging parameter that was associated with the 
prognosis of the disease. This finding has to be validated in larger cohorts. So far, previous 
reports on imaging features with prognostic value [18] in GC could not be reproduced. Our 
own previous finding that the presentation with a diffuse-symmetric involvement is prognostic 
[7] could not be further validated in the present cohort, probably since only 2 patients in the 
present cohort had a diffuse-symmetric presentation. Importantly, the presence of a focal 
contrast-enhancing tumor mass or a high lesion load with 6 or more brain regions involved 
was not prognostically relevant. These two imaging parameters were only associated with 
WHO grade 4 histology, which was prognostically irrelevant in our series and did not 
correlate with any prognostically relevant parameter such as GBM_MES/GBM_RTK2 
molecular profile, or MGMT promoter methylation status. Overall, it remains puzzling that 
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MRI features are disease-defining for GC but do not show any detectable relationship with 
prognostically relevant subgroups or molecular features.  
 
In summary, the dataset provided here suggests that GC is not a separate glioma entity: (1) 
the subgroups defined by DNA methylation profiling are the same as in non-GC glioma; a 
separate GC profile could not be detected. (2) the prognostic factor(s) are similar to those in 
non-GC glioma and GC-specific prognostic factors could not be detected. (3) Although MRI 
features are essential for making the diagnosis of GC they appear to be of limited prognostic 
relevance. Although the patient numbers analyzed here were small, and larger series 
reproducing these results would be desirable, it should be considered that GC more likely 
reflects a particularly widespread growth pattern that may be detected in different types of 
histologically and molecularly well-defined glioma entities, and does not represent a distinct 
entity of its own. The factors that drive the particularly infiltrative phenotype leading to the GC 
growth pattern have yet to be elucidated. However, the results presented here do not justify 
maintenance of GC as a separate disease entity and support its deletion in the upcoming 
revised  WHO classification of central nervous system tumors. 
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TABLES 
Table 1: Individual patient characteristics: demographic, imaging, histological and 
molecular features and outcome 
See separate file 
 
Table 2. Clinical and imaging characteristics. 
  N (%) 
Demographic data   
Age (median, range) 50.3 years (23.6-76.9 years)  
Gender Male  
Female 
 
12 (48) 
13 (52) 
Histological analysis   
Histology Glioblastoma 
Anaplastic Astrocytoma 
Anaplastic Oligoastrocytoma 
Oligoastrocytoma WHO II 
Oligodendroglioma WHO II 
Astrocytoma WHO II 
  10 (40) 
   6 (24) 
   2  (8) 
   2  (8) 
   1  (4) 
  4 (16) 
WHO grading WHO grade II  
WHO grade III  
WHO grade IV 
  8 (32) 
  9 (36) 
  8 (32) 
Oligodendroglial component Yes  
No 
 
  5 (20) 
20 (80) 
MRI characteristics   
Number of lobes involved 
Median (range) 
<6 
> 6 
12 (48) 
13 (52) 
 
Infratentorial involvement Yes 
No 
  5 (20) 
20 (80) 
 
Bilateral involvement Yes 
No 
22 (88) 
  3 (12) 
 
Diffuse symmetrical 
involvementa 
Yes  
No 
 
  2   (8) 
23 (92) 
Contrast-enhancing tumor 
mass on first MRI showing 
GC 
Yes  
No 
n.a. 
 
14 (56) 
10 (40) 
  1   (4) 
aaccording to Glas et al. [7] 
Abbreviations: GC, gliomatosis cerebri; n.a., not assessed 
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Table 3. Univariate Cox regression analysis regarding the prognostic value of the 
histological and molecular tumor classification for overall survival.  
 
 Median survival in months   Risk ratio  
(lower-upper 95% CI) 
P 
Univariate 
analysis 
 
Condition 1 Condition 2  Condition 1 vs.  
condition 2 
 
Histologically 
defined GBM 
yes no    
 
 
36.2 
 
34.6  1.33 (0.43-4.2) 0.62 
 
 
Any molecularly 
defined GBM 
 
 
GBM_RTK2 or 
GBM_MES 
yes 
14.1 
 
 
yes 
no 
36.3 
 
 
no 
  
3.18 (0.81-12.5) 
 
0.097 
 12.2 
 
37.1  9.83 (1.78-54.2) 0.009 
Abbreviations: GBM, glioblastoma WHO grade IV 
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Table 4. Univariate and multivariate Cox regression analysis regarding overall 
survival and single genetic factors. 
 
 Median survival in months  Risk ratio  
(lower-upper 95% CI) 
P 
Univariate 
analysis 
Condition 1 Condition 2  Condition 1 vs.  
condition 2 
 
MGMT promoter 
status 
methylated unmethylated    
 
 
>37.1 
 
8,9  0.09 (0.02-0.44) 0.004 
IDH / CIMP status 
 
 
1p/19q status 
mutant / 
positive 
36.3 
 
Codeleted 
wildtype / 
negative 
14.1 
 
Not codeleted 
  
0.31 (0.08-1.23) 
 
0.08 
 >16.5 
 
34.8  0.44 (0.05-3.6) 0.44 
Chromosome 7  yes  no    
gain 8.98 
 
>36.3  6.32 (1.78-22.5) 0.004 
EGFR amplification Yes no    
 7.9 
 
36.3  10.1 (2.0-51.1) 0.005 
9p21 deletion yes no    
 37.1 
 
34.6  1.15 (0.33-4.0) 0.82 
Chromosome 10  yes no    
deletion 12.2 
 
36.3  2.6 (0.77-8.73) 0.12 
CDK4 amplification yes no    
 36.2 
 
34.6  0.52 (0.1-2.6) 0.42 
MDM2 or MDM4  yes no    
amplification 14.1 
 
34.6  1.06 (0.28-4.1) 0.93 
      
Multivariate 
analysis 
     
MGMT promoter 
status 
methylated  unmethylated  0.16 (0.03-0.95) 0.04 
      
IDH / CIMP status mutant / 
positive 
wildtype / 
negative 
 1.27 (0.14-11.6) 0.83 
      
Chromosome 7 
gain 
yes  no  4.2 (0.49-36.3) 0.19 
      
EGFR amplification yes no  3.0 (0.56-16.3) 0,20 
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Table 5. Univariate Cox regression analysis regarding the prognostic value MRI 
features for overall survival.  
 
MRI appearance HR 95%CI P 
Infratentorial involvement, 
yes vs. no 
 
0.4 0.05 – 3.1 0.38 
Involvement of 6 or more 
lobes, yes vs. no 
 
1.08 0.33 – 3.5 0.9 
Bilateral involvement, yes vs. 
no 
 
0.67 0.08 – 5.4 0.71 
Contrast enhancing lesionsa, 
yes vs. no 
 
1.39 0.37 – 5.3 0.63 
aon the first MRI fulfilling the criteria of GC 
Abbreviations: HR, hazard ratio; CI, confidence interval 
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FIGURE LEGENDS 
 
Figure 1. Examples of neuroradiological, histological and genetic findings in selected cases 
of GC. Shown are contrast-enhanced T1- and T2-weighted MRI images (left panel), 
corresponding histological features on biopsy specimens (middle panel) and DNA copy 
number profiles determined by 450K methylation array profiling (right panel). The 
represented cases correspond to patients having GC with IDH mutant and 1p/19q codeleted 
oligodendroglioma (a), GC with IDH mutant diffuse astrocytoma (b), or GC with IDH wildtype 
glioblastoma also demonstrating EGFR amplification, homozygous CDKN2A deletion and 
chromosome 10 deletion (c). The histological pictures show hematoxylin-eosin (H&E) stained 
sections (original microscopic magnification: 400x). The copy number profiles represent gene 
dosages along chromosomes 1 to 22, X and Y. A stronger intensity of green or red colouring 
of probes indicates an increasing shift away from the baseline towards copy number gain or 
loss, respectively. Note 1p/19q codeletion in (a), MYCN gain in (b), and gains of 
chromosomes 7, losses of chromosome 10, homozygous deletion of CDKN2A as well as 
amplification of EGFR in (c). 
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Figure 2. Heatmap representation of an unsupervised hierarchical clustering analysis of 
450k methylation array profiles obtained from 25 GC patients, 10 normal brain samples, as 
well as 105 previously reported non-GC gliomas of different molecular types used for 
comparison [19,23]. The non-GC cases corresponded to various molecular subtypes of IDH 
wildtype glioblastomas (GBM_RTK1, GBM_RTK2, GBM_mes, GBM H3F3A-G34 mutant, 
GBM H3F3A-K27 mutant) as well as IDH mutant astrocytic and oligodendroglial tumors. (a) 
Results obtained with the entire tumor cohort using the 13,248 most variably methylated 
probes (standard deviation >0.25). Note that the 25 GC tumors (red bars) do not form a 
distinct cluster but are distributed across the different non-GC glioma subtypes. (b) Results 
obtained in the subset of IDH mutant gliomas using the top 5,000 most variably methylated 
probes. Note that subsets of IDH mutant GC tumors (red bars) either cluster together with 
the IDH mutant astrocytic gliomas (n=6) or the IDH mutant and 1p/19q codeleted 
oligodendroglial tumors (n=5). 
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Figure 3. Overall survival probability according to histological (a) or molecular (b-c) features 
of gliomatosis cerebri (GC). (a) No significant difference in overal survival between GC 
patients with histologically diagnosed WHO grade IV glioblastoma vs. patients with WHO 
grade II or III gliomas (p=0.62 logrank test). (b) GC patients with RTK2/classic glioblastoma 
(GBM_RTK2) or mesenchymal glioblastoma  (GBM_mes) demonstrate significantly shorter 
survival as vompared to patients with GC of other molecular subgroups (p=0.002, logrank 
test). (c) Prognostic stratification of GC patients according to MGMT promoter methylation 
status (p<0.001, logrank test). 
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